Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
Amgen Stock Climbs as Drug Growth Outruns Obesity Setback GuruFocus
Covered in this story
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.